A patient running a single-peptide protocol for recovery will pay differently from a patient running a three-peptide stack for longevity, body composition, and sleep optimization
This article is part of the Telehealth Process & Access cluster in the RenewMD Learn library
This is not marketing speculation
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes (Rosenstock et al.)
Hyperthyroidism is often treated with antithyroid drugs, which stop the overproduction of thyroid hormone